Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluticasone Discus 250 µg · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Symbicort, used twice daily (b.i.d) and as needed (prn) | DRUG | - |
| Budesonide Turbuhaler 200 µg | DRUG | - |
| Fluticasone Discus 250 µg | DRUG | - |
| Formoterol Turbuhaler 4.5 µg | DRUG | - |
| Terbutaline Turbuhaler 0.5 mg | DRUG | - |
| Salbutamol pressurized metered dose inhaler (pMDI) 100 µg | DRUG | - |
| Salmeterol Discus 50 µg | DRUG | - |
| Budesonide/Formoterol Turbuhaler 160/4.5 µg | DRUG | - |
| Fluticasone/Salmeterol Discus 250/50 µg | DRUG | - |
| Fluticasone/Salmeterol Discus 500/50 µg | DRUG | - |
| Theophylline 200 mg | DRUG | - |
| Theophylline 300 mg | DRUG | - |
| Singulair 10 mg | DRUG | - |
Inclusion Criteria: * Patients with asthma, either well-controlled on a regular therapy with a combination of long-acting beta-agonists and inhaled corticosteroids or symptomatic on therapy with inhaled corticosteroids alone. Exclusion Criteria: * Any other significant lung disease other than ast...
Fluticasone Discus 250 µg is an inhaled corticosteroid used for the treatment of persistent asthma in adults. It is being developed by AstraZeneca PLC (AZN) and is currently in Phase 3 clinical development. The drug is administered via a dry powder inhaler and is intended to reduce airway inflammation in asthma patients.
Fluticasone Discus 250 µg is developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with persistent asthma.
Fluticasone Discus 250 µg is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial, NCT00252863, has been completed, and the drug is being studied for the treatment of persistent asthma in adults.
Fluticasone Discus 250 µg has one completed Phase 3 clinical trial, NCT00252863, titled 'DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults.' The trial enrolled 1,600 participants in Germany and was not randomized or double-blinded.
Fluticasone Discus 250 µg is a specific formulation and dosage of fluticasone, an inhaled corticosteroid. The 'Discus' refers to the dry powder inhaler device used to deliver the medication. While fluticasone is the active ingredient, this product is specifically designed for asthma treatment and is being developed by AstraZeneca.